Quantitative MRI of Prostate Cancer as a Biomarker and Guide for Treatment
Licensed under
Category
Published on
Abstract
Prostate cancer (PCa) remains the most common malignancy and third leading cause of cancer-related mortality in American men with incidence estimated at >450,000 cases per year by 2015. The natural history of PCa is remarkably heterogeneous and still not completely understood. The need for an accurate non-invasice imaging tool increases as the number of men with localized disease increases. With the recent advances in multiparametric MRI (mpMRI) [1], there is a hope that the various MR imaging markers, such as Apparent Diffusion Coefficient (ADC) derived from Diffusion Weighted (DWI) MRI and Dynamic Contrast Enhanced MRI (DCE-MRI) can be applied for PCa localization and grading [2], and in the evaluation of the response to treatment [1].
Cite this work
Researchers should cite this work as follows: